Merck & Co., Inc. (NYSE:MRK) has been upgraded by Wells Fargo to Overweight with a price target of $125, citing recent business developments and pipeline advancements. The company is expected to grow revenue into the early 2030s. Additionally, Merck announced a $9.2 billion acquisition of Cidara Therapeutics, expanding its pipeline. Management estimates that its 20-drug developmental pipeline could generate up to $50 billion in annual revenue. The company also increased its quarterly dividend and is known for its strong oncology portfolio and other medical treatments.

Read more at Yahoo Finance: Wells Fargo Upgrades Merck (MRK) to Overweight, Raises Price Target to $125